| Roberto Diaz-rohena, MD | |
|
1309 E Ridge Rd, Suite 1, Mcallen, TX 78503-1517 | |
| (956) 631-8875 | |
| (956) 682-6280 |
| Full Name | Roberto Diaz-rohena |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Location | 1309 E Ridge Rd, Mcallen, Texas |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1972584407 | NPI | - | NPPES |
| 137745912 | Medicaid | TX |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | J4775 (Texas) | Primary |
| Entity Name | Valley Retina Institute P.a. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1225139942 PECOS PAC ID: 7113903659 Enrollment ID: O20040625000871 |
News Archive
Bayhill Therapeutics Inc, a clinical-stage biopharmaceutical company utilizing its proprietary BHT-DNA™ platform to develop novel and targeted autoimmune and immune-mediated disease treatments, today announced the successful clearance of an IND with the US FDA for BHT-3034, a disease-modifying DNA plasmid vaccine immunotherapy for patients with the autoimmune neuromuscular junction disease myasthenia gravis.
Barriers to the distribution of life saving vaccines in low income countries can and should be overcome, say experts in this week's issue of the BMJ.
Martin Jinek, a professor at the University of Zurich's Department of Biochemistry, was presented with the 2015 Vallee Young Investigator Award. The international prize is awarded to young researchers for outstanding achievements in biomedicine and carries USD 250,000 in prize money.
The researchers from Stanford School of Medicine and ShangaiTech University show that the growth of a coronavirus disease (COVID-19) outbreak does not behave in accordance with an exponential growth law, but instead slows down exponentially with time from the very first days. Their thought-provoking findings can be currently found in the medRxiv* preprint server.
Calithera Biosciences, a company developing novel oncology therapeutics, today announced the completion of a Series A financing totaling $40 million. Morgenthaler Ventures led the financing with U.S. Venture Partners, Advanced Technology Ventures, Delphi Ventures and Mission Bay Capital also participating in the round. The capital will be used to support the company's pioneering efforts to develop activators of caspases, the proteases that promote apoptotic cell death, for the treatment of cancer and other proliferative diseases.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Roberto Diaz-rohena, MD Po Box 531848, Harlingen, TX 78553-1848 Ph: (956) 631-8875 | Roberto Diaz-rohena, MD 1309 E Ridge Rd, Suite 1, Mcallen, TX 78503-1517 Ph: (956) 631-8875 |
News Archive
Bayhill Therapeutics Inc, a clinical-stage biopharmaceutical company utilizing its proprietary BHT-DNA™ platform to develop novel and targeted autoimmune and immune-mediated disease treatments, today announced the successful clearance of an IND with the US FDA for BHT-3034, a disease-modifying DNA plasmid vaccine immunotherapy for patients with the autoimmune neuromuscular junction disease myasthenia gravis.
Barriers to the distribution of life saving vaccines in low income countries can and should be overcome, say experts in this week's issue of the BMJ.
Martin Jinek, a professor at the University of Zurich's Department of Biochemistry, was presented with the 2015 Vallee Young Investigator Award. The international prize is awarded to young researchers for outstanding achievements in biomedicine and carries USD 250,000 in prize money.
The researchers from Stanford School of Medicine and ShangaiTech University show that the growth of a coronavirus disease (COVID-19) outbreak does not behave in accordance with an exponential growth law, but instead slows down exponentially with time from the very first days. Their thought-provoking findings can be currently found in the medRxiv* preprint server.
Calithera Biosciences, a company developing novel oncology therapeutics, today announced the completion of a Series A financing totaling $40 million. Morgenthaler Ventures led the financing with U.S. Venture Partners, Advanced Technology Ventures, Delphi Ventures and Mission Bay Capital also participating in the round. The capital will be used to support the company's pioneering efforts to develop activators of caspases, the proteases that promote apoptotic cell death, for the treatment of cancer and other proliferative diseases.
› Verified 3 days ago
Vimal Sarup, MD Ophthalmology Medicare: Medicare Enrolled Practice Location: 1309 E Ridge Rd Ste 1, Mcallen, TX 78503 Phone: 956-631-8875 Fax: 956-683-1502 | |
Dr. Rachel Ann Gelman, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 5201 N G St, Mcallen, TX 78504 Phone: 956-305-5795 Fax: 956-618-4639 | |
Dr. Raul Adrian Pena, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1400 E Ridge Rd Ste 10, Mcallen, TX 78503 Phone: 956-661-8733 Fax: 956-661-8724 | |
Dr. Melissa Ixcamey, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1309 E Ridge Rd Ste 1, Mcallen, TX 78503 Phone: 956-844-6440 | |
Cooper M Clark, D.O. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1309 E Ridge Rd, Suite 1, Mcallen, TX 78503 Phone: 956-631-8875 Fax: 956-682-6280 | |
Dr. Wade Alan Graham, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1400 E Ridge Rd Ste 3, Mcallen, TX 78503 Phone: 956-429-4900 Fax: 956-429-4901 | |
Dr. Nehal Rashmikant Patel, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1309 East Ridge Road, Suite 1, Mcallen, TX 78503 Phone: 956-631-8875 Fax: 956-631-9134 |